Quest Diagnostics Incorporated

NYSE:DGX 株式レポート

時価総額：US$21.1b

Quest Diagnostics 将来の成長

Future 基準チェック /16

Quest Diagnostics利益と収益がそれぞれ年間9.9%と4.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に16% 9.6%なると予測されています。

主要情報

9.9%

収益成長率

9.58%

EPS成長率

Healthcare 収益成長18.3%
収益成長率4.3%
将来の株主資本利益率16.02%
アナリストカバレッジ

Good

最終更新日18 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • May 13

DGX: Refreshed 2026 Outlook And Margin Assumptions Will Sustain Safe Haven Appeal

Quest Diagnostics' analyst price target has been revised to $223.25 from $218.19 as analysts factor in recent target increases across the Street and updated assumptions around discount rate, profit margins and future P/E multiples. Analyst Commentary Recent Street research around Quest Diagnostics has centered on refreshed valuation work and price target changes, with several firms adjusting their numbers based on updated assumptions for discount rates, profit margins and future P/E multiples.
Seeking Alpha • May 07

Quest Diagnostics: Updating Levels After Q1 Earnings

Summary Quest Diagnostics delivered strong Q1 results with 9.2% revenue growth and 13% EPS growth, driving management to raise 2026 guidance. DGX's growth is fueled by advanced diagnostics, robust consumer and hospital channels, and efficiency gains from AI and automation. Key risks include margin pressure from lower-priced partnership volumes and potential Medicare reimbursement cuts under PAMA. I maintain a 5/5 conviction rating, raising my Buy Threshold to $197 and holding the Sell Target at $227, reflecting confidence in DGX's long-term outlook. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 20

DGX: Organic Guidance And Capital Returns Will Sustain Safe Haven Appeal

Analyst price targets for Quest Diagnostics have been adjusted slightly lower to $218.19 from $218.50, as analysts factor in updated views on revenue growth, profit margins, and long term P/E assumptions following a series of recent target changes across the coverage universe. Analyst Commentary Recent research updates point to a mixed but generally constructive stance on Quest Diagnostics, with multiple target changes and one fresh list inclusion helping to frame how analysts are thinking about valuation, execution, and growth risk.
ナラティブの更新 • Apr 05

DGX: Organic Guidance And Capital Returns Will Support Safe Haven Profile

Analysts have raised their price targets on Quest Diagnostics by between $5 and $30, largely pointing to recently issued organic revenue growth guidance and viewing the broader diagnostic lab space as a relative safe haven within healthcare services. Analyst Commentary Recent Street research around Quest Diagnostics and its closest peer highlights a constructive setup for the broader diagnostic lab group, with price target moves on Quest generally framed against views that the sector can act as a relative safe haven within healthcare services.
ナラティブの更新 • Mar 22

DGX: Premium Multiple And Capital Returns Look Supported By Organic Revenue Guidance

Analysts have raised their price targets on Quest Diagnostics by a range of $5 to $30, citing the company’s recent organic revenue growth guidance and viewing the diagnostic testing space as a relative safe haven within healthcare services. Analyst Commentary Recent research on Quest Diagnostics highlights a cluster of higher price targets and an upgrade, with many investors treating large diagnostic labs as a relatively defensive corner of healthcare services.
ナラティブの更新 • Mar 07

DGX: Fair Outlook As Premium Multiple And Capital Returns Shape Future Earnings

Analysts raised their price target on Quest Diagnostics by about $1 to $218.50, reflecting refined assumptions that include slightly higher revenue growth, a similar discount rate, modestly adjusted profit margins, and a small change in future P/E expectations, supported by broadly positive recent research across the diagnostic lab space. Analyst Commentary Street research around Quest Diagnostics has focused on how the company is positioned within the broader diagnostic lab group, with recent moves in peer guidance and a series of price target changes shaping sentiment on both upside potential and execution risk.
ナラティブの更新 • Feb 21

DGX: Fair Outlook As Higher Payouts And Consumer Labs Support Future Earnings

Analysts have lifted their price target on Quest Diagnostics by about $18, reflecting slightly higher modeled revenue growth and a somewhat richer future P/E assumption, even as projected profit margins are trimmed in line with recent Street research that has broadly raised targets across the lab testing group. Analyst Commentary Bullish analysts have broadly raised their price targets on Quest Diagnostics, reflecting a more constructive view on the lab testing group as a whole and on Quest's positioning within it.
ナラティブの更新 • Feb 06

DGX: Fair Outlook As Consumer Lab Partnerships And Margins Support Future Earnings

Analysts have inched up their fair value estimate for Quest Diagnostics to about $199 per share, a move they tie to slightly higher margin and P/E assumptions following recent research that points to potential upside to current earnings estimates. Analyst Commentary Recent Street research points to potential upside to current earnings estimates for Quest Diagnostics, which is feeding into a more constructive view on the stock’s valuation and execution risk.
ナラティブの更新 • Jan 23

DGX: Future Consumer Lab Partnerships And Neurology Tests Will Support Balanced Outlook

Analysts have inched up their price target on Quest Diagnostics to about $198.38 from roughly $198.06, reflecting refreshed assumptions around slightly higher revenue growth, a small adjustment to profit margins, and a near steady forward P/E outlook. What's in the News Hims & Hers Health is offering lab testing that it views as a potential US$1b business, with customers accessing testing through Quest Diagnostics and then receiving results and care plans through the Hims platform (Wall Street Journal).
ナラティブの更新 • Jan 06

DGX: Future Lab Partnerships And Testing Pipeline Will Support Bullish Outlook

Analysts lifted their price target for Quest Diagnostics by about US$1 to roughly US$198, citing recent Q3 results with sales and earnings ahead of consensus; raised full year guidance; firm organic volume trends; and growing interest in longer term opportunities, such as the Haystack MRD test and a generally supportive lab testing backdrop. Analyst Commentary Street research following the Q3 report points to a generally constructive tone, with multiple firms lifting their price targets and highlighting both execution on current fundamentals and potential longer term growth drivers.
ナラティブの更新 • Dec 14

DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook

Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.
ナラティブの更新 • Nov 29

DGX: Future Volume Gains And Lab Partnerships Will Support Balanced Outlook

The analyst price target for Quest Diagnostics was modestly increased to $197.31 from $197.25. Analysts cited stronger-than-expected earnings, raised guidance, and continued positive core trends as the rationale for the update.
ナラティブの更新 • Nov 15

DGX: Future Revenue Expansion And Partnerships Will Balance Near-Term Risks

Quest Diagnostics saw its analyst price target increase, with several firms now projecting new targets between $195 and $215 per share. Analysts cite strong quarterly results and ongoing positive momentum in core business trends.
ナラティブの更新 • Nov 01

DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum

Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.
ナラティブの更新 • Oct 18

Preventive Diagnostics And Automation Will Shape Future Healthcare

Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.
分析記事 • Aug 20

Earnings Not Telling The Story For Quest Diagnostics Incorporated (NYSE:DGX)

Quest Diagnostics Incorporated's ( NYSE:DGX ) price-to-earnings (or "P/E") ratio of 21.6x might make it look like a...
分析記事 • Jun 21

Return Trends At Quest Diagnostics (NYSE:DGX) Aren't Appealing

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
Seeking Alpha • Jan 28

Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation

Summary Quest Diagnostics' is reporting good numbers for the last 3 quarters, indicating the end of its dull period, which started post COVID. The street and management are expecting mid-single-digit topline growth and high-single-digit bottom-line growth. However, I have a rather moderate opinion on future top-line and bottom-line performance given the poor execution track record and higher leverage, limiting inorganic growth potential. Based on my fair value estimates, the company does not offer substantial upside from here. Read the full article on Seeking Alpha
Seeking Alpha • Oct 24

Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat

Summary Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects significant growth from recent and upcoming acquisitions, projecting double-digit revenue growth for Q4. Despite risks like economic downturns and inflation, I maintain a bullish outlook on DGX, adjusting my Buy Threshold to $150 and Sell Target to $227. DGX's technical indicators and seasonality trends support a bullish trend, prompting me to stay vigilant on trading behavior to capitalize on growth opportunities. Read the full article on Seeking Alpha

業績と収益の成長予測

NYSE:DGX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202812,8831,3231,4221,99711
12/31/202712,3771,1901,3301,90416
12/31/202611,8541,0921,4521,86716
3/31/202611,2781,0201,3261,850N/A
12/31/202511,0359881,3591,886N/A
9/30/202510,8509631,3931,885N/A
6/30/202510,5229451,2241,678N/A
3/31/202510,1588921,0561,494N/A
12/31/20249,8728669091,334N/A
9/30/20249,5398381,0231,397N/A
6/30/20249,3468368751,248N/A
3/31/20249,2878429471,332N/A
12/31/20239,2528508641,272N/A
9/30/20239,2977595961,079N/A
6/30/20239,4887908781,374N/A
3/31/20239,6037898641,332N/A
12/31/20229,8839421,3141,718N/A
9/30/202210,2941,2301,4641,865N/A
6/30/202210,5821,4791,5521,924N/A
3/31/202210,6791,8741,6021,982N/A
12/31/202110,7881,9881,8302,233N/A
9/30/202111,0462,1751,8722,293N/A
6/30/202111,0582,2382,1712,594N/A
3/31/202110,3351,7942,0682,489N/A
12/31/20209,4371,4251,5872,005N/A
9/30/20208,3611,1011,3841,812N/A
6/30/20207,5317498161,249N/A
3/31/20207,6577717791,215N/A
12/31/20197,726835N/A1,243N/A
9/30/20197,639709N/A1,190N/A
6/30/20197,572707N/A1,293N/A
3/31/20197,538720N/A1,295N/A
12/31/20187,531733N/A1,200N/A
9/30/20187,557860N/A1,228N/A
6/30/20187,524808N/A1,188N/A
3/31/20187,469782N/A1,159N/A
12/31/20177,402769N/A1,175N/A
9/30/20177,398671N/A1,156N/A
6/30/20177,427701N/A1,095N/A
3/31/20177,469702N/A1,112N/A
12/31/20167,214642N/A1,116N/A
9/30/20167,503675N/A1,037N/A
6/30/20167,498825N/A948N/A
3/31/20167,517748N/A922N/A
12/31/20157,493706N/A821N/A
9/30/20157,527703N/A852N/A
6/30/20157,551491N/A911N/A

アナリストによる今後の成長予測

収入対貯蓄率: DGXの予測収益成長率 (年間9.9% ) は 貯蓄率 ( 3.5% ) を上回っています。

収益対市場: DGXの収益 ( 9.9% ) US市場 ( 16.8% ) よりも低い成長が予測されています。

高成長収益: DGXの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: DGXの収益 ( 4.3% ) US市場 ( 11.6% ) よりも低い成長が予測されています。

高い収益成長: DGXの収益 ( 4.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DGXの 自己資本利益率 は、3年後には低くなると予測されています ( 16 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/20 03:06
終値2026/05/20 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Quest Diagnostics Incorporated 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。36

アナリスト機関
Jasper HellwegArgus Research Company
Eric ColdwellBaird
Luke SergottBarclays